Literature DB >> 19012866

Progranulin mutation causes frontotemporal dementia in the Swedish Karolinska family.

Huei-Hsin Chiang1, Lina Rosvall, Jesper Brohede, Karin Axelman, Behnosh F Björk, Inger Nennesmo, Tiina Robins, Caroline Graff.   

Abstract

BACKGROUND: Frontotemporal dementia (FTD) is a neurodegenerative disease characterized by cognitive impairment, language dysfunction, and/or changes in personality. Recently it has been shown that progranulin (GRN) mutations can cause FTD as well as other neurodegenerative phenotypes.
METHODS: DNA from 30 family members, of whom seven were diagnosed with FTD, in the Karolinska family was available for GRN sequencing. Fibroblast cell mRNA from one affected family member and six control individuals was available for relative quantitative real-time polymerase chain reaction to investigate the effect of the mutation. Furthermore, the cDNA of an affected individual was sequenced.
RESULTS: Clinical and neuropathologic findings of a previously undescribed family branch are presented. A frameshift mutation in GRN (g.102delC) was detected in all affected family members and absent in four unaffected family members older than 70 years. Real-time polymerase chain reaction data showed an approximately 50% reduction of GRN fibroblast mRNA in an affected individual. The mutated mRNA transcripts were undetectable by cDNA sequencing.
CONCLUSIONS: Segregation and RNA analyses showed that the g.102delC mutation, previously reported, causes FTD in the Karolinska family. Our findings add further support to the significance of GRN in FTD etiology and the presence of modifying genes, which emphasize the need for further studies into the mechanisms of clinical heterogeneity. However, the results already call for attention to the complexity of predictive genetic testing of GRN mutations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19012866     DOI: 10.1016/j.jalz.2008.09.001

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  6 in total

1.  Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels.

Authors:  Carlos Cruchaga; Caroline Graff; Huei-Hsin Chiang; Jun Wang; Anthony L Hinrichs; Noah Spiegel; Sarah Bertelsen; Kevin Mayo; Joanne B Norton; John C Morris; Alison Goate
Journal:  Arch Neurol       Date:  2011-01-10

2.  Progranulin mutations result in impaired processing of prosaposin and reduced glucocerebrosidase activity.

Authors:  Clarissa Valdez; Daniel Ysselstein; Tiffany J Young; Jianbin Zheng; Dimitri Krainc
Journal:  Hum Mol Genet       Date:  2020-03-27       Impact factor: 6.150

3.  Progranulin-mediated deficiency of cathepsin D results in FTD and NCL-like phenotypes in neurons derived from FTD patients.

Authors:  Clarissa Valdez; Yvette C Wong; Michael Schwake; Guojun Bu; Zbigniew K Wszolek; Dimitri Krainc
Journal:  Hum Mol Genet       Date:  2017-12-15       Impact factor: 6.150

4.  Suberoylanilide hydroxamic acid increases progranulin production in iPSC-derived cortical neurons of frontotemporal dementia patients.

Authors:  Sandra Almeida; Fuying Gao; Giovanni Coppola; Fen-Biao Gao
Journal:  Neurobiol Aging       Date:  2016-03-09       Impact factor: 4.673

5.  Novel progranulin mutations with reduced serum-progranulin levels in frontotemporal lobar degeneration.

Authors:  Huei-Hsin Chiang; Charlotte Forsell; Lena Lilius; Linn Öijerstedt; Steinunn Thordardottir; Krishnan Shanmugarajan; Marie Westerlund; Inger Nennesmo; Håkan Thonberg; Caroline Graff
Journal:  Eur J Hum Genet       Date:  2013-03-06       Impact factor: 4.246

6.  Pooled-DNA sequencing identifies novel causative variants in PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer's disease Ibero-American cohort.

Authors:  Sheng Chih Jin; Pau Pastor; Breanna Cooper; Sebastian Cervantes; Bruno A Benitez; Cristina Razquin; Alison Goate; Carlos Cruchaga
Journal:  Alzheimers Res Ther       Date:  2012-08-20       Impact factor: 6.982

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.